Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

102.89
+1.291.27%
Post-market: 102.890.00000.00%19:31 EDT
Volume:650.45K
Turnover:66.78M
Market Cap:5.08B
PE:-17.83
High:103.83
Open:101.13
Low:100.00
Close:101.60
Loading ...

Hunter R. Murdock, General Counsel, Reports Disposal of Axsome Therapeutics Inc. Common Shares

Reuters
·
1 hour ago

Axsome Therapeutics to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting

Reuters
·
Yesterday

Axsome Therapeutics supports Migraine, Headache Awareness Month

TIPRANKS
·
16 Jun

Strong Growth Potential and Market Penetration Drive Buy Rating for Axsome Therapeutics

TIPRANKS
·
16 Jun

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
12 Jun

RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating

MT Newswires Live
·
12 Jun

Mizuho Securities Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
12 Jun

Axsome Therapeutics Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference

Reuters
·
11 Jun

Axsome Therapeutics COO Mark Jacobson Reports Disposal of Common Shares

Reuters
·
11 Jun

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating

MT Newswires Live
·
10 Jun

BRIEF-Axsome Therapeutics Announces Availability Of Symbravo® For The Acute Treatment Of Migraine

Reuters
·
10 Jun

Axsome Therapeutics announces availability of SYMBRAVO in U.S.

TIPRANKS
·
10 Jun

Axsome Therapeutics Inc. : Deutsche Bank Cuts Target Price to $185 From $190

THOMSON REUTERS
·
10 Jun

Axsome Therapeutics Announces Availability of Symbravo® (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine With or Without Aura in Adults

THOMSON REUTERS
·
10 Jun

Axsome Therapeutics Shareholders Approve Key Proposals at Meeting

TIPRANKS
·
10 Jun

Axsome Therapeutics Inc. Conducted Annual Stockholder Meeting

Reuters
·
10 Jun

Oppenheimer Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
10 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Chip Stocks, EchoStar

Reuters
·
10 Jun

Axsome Therapeutics’ Growth Prospects Remain Strong Despite FDA Setback on AXS-14

TIPRANKS
·
09 Jun

Axsome Therapeutics Shares Down 1.8% After FDA Refuses to Review Co's Application for Fibromyalgia Drug

THOMSON REUTERS
·
09 Jun